Institute for Clinical and Economic Review Releases Evidence Report on Treatments for Cystic Fibrosis
April 28, 2020
April 28, 2020
BOSTON, Massachusetts, April 28 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) released an Evidence Report assessing the comparative clinical effectiveness and value of elexacaftor/tezacaftor/ivacaftor (Trikafta(R), Vertex Pharmaceuticals) for the treatment of cystic fibrosis (CF). ICER also examined new data that have become available since its May 2018 review of three related CF treatments: . . .
The Institute for Clinical and Economic Review (ICER) released an Evidence Report assessing the comparative clinical effectiveness and value of elexacaftor/tezacaftor/ivacaftor (Trikafta(R), Vertex Pharmaceuticals) for the treatment of cystic fibrosis (CF). ICER also examined new data that have become available since its May 2018 review of three related CF treatments: . . .